AMGEN ANNOUNCES WEBCAST OF 2022 FOURTH QUARTER AND FULL YEAR FINANCIAL RESULTS

Rhea-AI Summary

Amgen (NASDAQ:AMGN) will release its fourth quarter and full year 2022 financial results on January 31, 2023, post-market close. A conference call with management, including CEO Robert A. Bradway, will follow at 4:30 p.m. ET. The call and additional financial presentations will be accessible via the Amgen website.

Amgen, a leader in biotechnology, focuses on developing innovative therapeutics for patients with serious illnesses. The company is recognized as one of the top independent biotech firms and is part of the Dow Jones Industrial Average and Nasdaq-100.

Positive

• Anticipation for the release of fourth quarter and full year 2022 financial results on January 31, 2023.
• Continued commitment to innovative human therapeutics in areas of high unmet medical need.

Negative

• None.

THOUSAND OAKS, Calif., Jan. 26, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2022 financial results on Tuesday, Jan. 31, 2023, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 4:30 p.m. ET. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen's senior management team.

Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

About Amgen 
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. 

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2022, Amgen was named one of the "World's Best Employers" by Forbes and one of "America's 100 Most Sustainable Companies" by Barron's.

For more information, visit Amgen.com and follow us on Twitter, LinkedIn, Instagram, TikTok and YouTube. 

CONTACT: Amgen, Thousand Oaks 
Jessica Akopyan, 805-447-0974 (media) 
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors) 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-announces-webcast-of-2022-fourth-quarter-and-full-year-financial-results-301731833.html

SOURCE Amgen

FAQ

When is Amgen's fourth quarter and full year 2022 financial results announcement?

Amgen will announce its fourth quarter and full year 2022 financial results on January 31, 2023.

What time is the Amgen financial results conference call?

The conference call will take place at 4:30 p.m. ET on January 31, 2023.

Who will participate in the Amgen conference call?

Robert A. Bradway, CEO of Amgen, and other senior management members will participate in the call.

Where can I access the Amgen financial results webcast?

The webcast will be available on the Amgen website under the Investors section.